UK-based Antibody Analytics secures multi-million-GBP investment from NorthEdge. a private equity firm headquartered in Manchester. This investment is not just a financial boost to the company; it’s a catalyst for exciting growth, innovation, and global impact.
At Antibody Analytics, we stand at the forefront of pre-clinical drug discovery, supporting biopharmaceutical companies worldwide in their quest to develop ground-breaking solutions for their challenges. This investment represents a significant leap forward for us, paving the way for remarkable developments.
Expanded facilities for cutting-edge research services: With NorthEdge’s support, we’re expanding our facilities. The Antibody Analytics Discovery Centre will get further state-of-the-art technology and equipment in house with larger lab capacity.
Job creation and economic growth: Our growth will not be limited to Antibody Analytics alone. This investment promises numerous job opportunities within the broader Scottish Life Sciences sector, contributing to the stability and prosperity of the region in line with Scotland’s ambitious Life Sciences strategy.
Global leadership in immunology research services: Antibody Analytics will continue to be a regional life sciences powerhouse while solidifying its position as a recognised global leader in discovery and pre-clinical immunology research services.
Commitment to a healthier future: Our CEO, Andy Upsall, emphasises that this investment will empower us to develop technologies and services that address the industry’s demands, ultimately impacting patient outcomes and advancing life sciences.
Andy Upsall said: “This marks a watershed moment for Antibody Analytics. We’re committed to using this investment as a tool – to create jobs, expand our facilities, solidify our global standing and allow us to realise our vision of a healthier future for all. With this investment, we will continue to develop technologies and provide services that address the challenges the industry demands. Now more than ever, the developers of innovative biotherapeutics require specialist solutions, as they forge their way through the increasingly difficult and expensive drug development pathway. This is just the beginning of our journey to further impact patient outcomes and drive advancements in life sciences”.
Liam May, Director at NorthEdge, added: “We’re thrilled to be backing Andy and the team at Antibody Analytics to support this extremely exciting stage of growth. At NorthEdge, we have a strong cultural alignment with Antibody Analytics and we are committed to investing in people, technology and infrastructure to support businesses that improve global health outcomes. Antibody Analytics has a track record of developing strategically important services, alongside a pipeline of R&D projects that will further cement its reputation as a leader in its field. The value creation plan leverages the company’s culture of innovation and blends it with a continued focus on quality, client service and a market-leading employee value proposition to facilitate scale”.
About Antibody Analytics
At Antibody Analytics, we believe that patients should receive the finest medications and scientists should have access to the best data. Under the leadership of a team of gifted and motivated scientists, we approach biological issues with an open mind and produce exquisitely crafted, well-developed, and qualified bioassays.